BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$6.17 USD
-0.06 (-0.96%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $6.16 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Brokerage Reports
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 141 - 160 ( 175 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q11 - PHASE 2 PROGRAM IN GOUT EXPANDS - KEY DATA CATALYST BY YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q11 - PHASE 2 PROGRAM IN GOUT EXPANDS - KEY DATA CATALYST BY YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Investors Spooked By Events in Japan - Creates Additional Buying Opportunity
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Investors Spooked By Events in Japan - Creates Additional Buying Opportunity
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Non-Dilutive Monetization of Shionogi Payments Drives Development of the Pipeline
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Non-Dilutive Monetization of Shionogi Payments Drives Development of the Pipeline
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Contract Extension Takes Peramivir to the Goal Line - Gout Is Key 2011 Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Contract Extension Takes Peramivir to the Goal Line - Gout Is Key 2011 Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q10 - A RISING PLAYER IN GOUT WITH ADVANCED PHASE 2B TRIAL UNDERWAY
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q10 - A RISING PLAYER IN GOUT WITH ADVANCED PHASE 2B TRIAL UNDERWAY
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Safety Study Supports Once Daily Dose of Peramivir for Inpatients - Gout Remains Key Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
2010 RECAP & 2011 PREVIEW
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Gout Program Moves Into Advanced Phase 2 Development
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y